腸道菌群代謝物的失調(diào)在動脈粥樣硬化（atherosclerosis，AS）患者中廣泛存在，且與AS的發(fā)展密切相關(guān)。中藥活性成分在治療AS方面展現(xiàn)出獨(dú)特優(yōu)勢，可通過重塑腸道微環(huán)境和調(diào)節(jié)腸道菌群代謝物來發(fā)揮抗AS活性。以腸道菌群代謝物為靶點(diǎn)，探索中醫(yī)藥治療手段與AS之間的科學(xué)相關(guān)性，有望成為一種前景廣闊的AS治療新途徑。通過系統(tǒng)闡明腸道菌群代謝物與AS發(fā)生發(fā)展的相關(guān)性，及中藥活性成分調(diào)控腸道菌群代謝產(chǎn)物改善AS的藥理活性及作用機(jī)制，為中醫(yī)防治AS提供新視角和藥物開發(fā)新策略。

The imbalance of intestinal flora metabolites is widely present in patients with atherosclerosis (AS) and is closely related to the development of AS. The active ingredients of traditional Chinese medicine (TCM) show unique advantages in treatment of AS, which can exert anti-AS activity by reshaping the intestinal microenvironment and regulating the metabolites of gut microbiota. Taking the metabolites of gut microbiota as the target, exploring the scientific correlation between TCM treatment and AS is expected to become a new way of AS treatment with broad prospects. By systematically elucidating the correlation between gut microbiota metabolites and the occurrence and development of AS, and the pharmacological activity and mechanism of TCM active components regulating gut microbiota metabolites to improve AS, it provides a new perspective and new drug development strategy for the prevention and treatment of AS in TCM.

R285

黑龍江省自然科學(xué)基金項目（PL2024H239）